Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Anti-Cancer Microbiome Therapeutic Receives FDA IND Clearance in Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Scioto Biosciences","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Scioto Biosciences Receives Series B Investment from Genome & Company","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genome & Company Announces First Patient Dosed in Phase 1\/1b Study of GEN-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genome and Company Ink 2nd Clinical Trial Collaboration and Supply Agreement with Merck KGA and Pfizer for Immuno-Oncology Microbiome Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Genome & Company","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genome and Company Announces Clinical Trial Collaboration with MSD to Evaluate 'GEN-001' in Combination of KEYTRUDA\u00ae (pembrolizumab) in Phase 2 Clinical Trial in Biliary Tract Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Interim Analysis of 'GEN-001' Plus Avelumab (Bavencio\u00ae) Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Genome & Company

    Menu

    Genome & Company

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Genome & Company

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Positive Results from Interim Analysis of 'GEN-001' Plus Avelumab (Bavencio®) Phase II Trial

              Details:

              GEN-001 is being developed as an orally administered microbiome therapeutic with Lactococcus lactis, a single strain bacteria isolated from a healthy human. Its anticancer efficacy was proven by activating immune activity of cancer cells.

              Lead Product(s): GEN-001,Avelumab

              Therapeutic Area: Oncology Product Name: GEN-001

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genome & Company

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genome and Company Announces Clinical Trial Collaboration with MSD to Evaluate 'GEN-001' in Combination of KEYTRUDA® (pembrolizumab) in Phase 2 Clinical Trial in Biliary T...

              Details:

              Upon the execution of the agreement, Genome will conduct a phase 2 clinical trial to evaluate the safety and efficacy of its immuno-oncology microbiome therapeutic, GEN-001, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with biliary tract cancer.

              Lead Product(s): GEN-001,Pembrolizumab

              Therapeutic Area: Oncology Product Name: GEN-001

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: MSD Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genome & Company

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genome and Company Ink 2nd Clinical Trial Collaboration and Supply Agreement with Merck KGA and Pfizer for Immuno-Oncology Microbiome Study

              Details:

              The collaboration follows in just a year after signing the first agreement with Merck KGaA, Darmstadt, Germany and Pfizer in December 2019 to conduct the first combination clinical trial of avelumab (BAVENCIO®) and GEN-001.

              Lead Product(s): GEN-001,Avelumab

              Therapeutic Area: Oncology Product Name: GEN-001

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Merck Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genome & Company

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genome & Company Announces First Patient Dosed in Phase 1/1b Study of GEN-001

              Details:

              The phase 1 study aims to determine the RP2D (recommended Phase 2 dose) of GEN-001 in combination with BAVENCIO® (avelumab).

              Lead Product(s): GEN-001,Avelumab

              Therapeutic Area: Oncology Product Name: GEN-001

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genome & Company

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scioto Biosciences Receives Series B Investment from Genome & Company

              Details:

              Funding will be used to support ongoing clinical development of Scioto’s lead product, SB-121, as a microbiome treatment for diseases affecting the gut-brain axis and gut injury.

              Lead Product(s): SB-121

              Therapeutic Area: Gastroenterology Product Name: SB-121

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: Scioto Biosciences

              Deal Size: $26.5 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing August 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genome & Company

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Anti-Cancer Microbiome Therapeutic Receives FDA IND Clearance in Asia

              Details:

              Genome & Company which sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug receives FDA IND clearance for GEN-001,

              Lead Product(s): GEN-001,Avelumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Genome & Company

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

              Details:

              Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.

              Lead Product(s): GEN-001,Avelumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY